Johnson & Johnson

NYSE-JNJ

Basic

Market Cap
$348.43B
EV
$355.94B
Shares Out
2,409.78M
Revenue
$85.65B
Employees
131,900

Margins

Gross
69.33%
EBITDA
35.81%
Operating
27.64%
Pre-Tax
26.61%
Net
47.37%
FCF
20.88%

Returns (5Yr Avg)

ROA
10.92%
ROTA
96.84%
ROE
28.96%
ROCE
17.65%
ROIC
16.35%

Valuation (TTM)

P/E
—
P/B
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
EV/Gross Profit
—

Valuation (NTM)

Price Target
$173.26
P/E
—
PEG
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—

Financial Health

Cash
$22.93B
Net Debt
$7,505M
Debt/Equity
0.44
EBIT/Interest
31.23

Growth (CAGR)

Rev 3Yr
0.56%
Rev 5Yr
0.97%
Rev 10Yr
1.79%
Dil EPS 3Yr
41.73%
Dil EPS 5Yr
24.45%
Dil EPS 10Yr
11.92%
Rev Fwd 2Yr
3.3%
EBITDA Fwd 2Yr
4.31%
EPS Fwd 2Yr
5.18%
EPS LT Growth Est
4.18%

Dividends

Yield
—
Payout
61.82%
DPS
$4.76
DPS Growth 3Yr
5.62%
DPS Growth 5Yr
5.75%
DPS Growth 10Yr
6.07%
DPS Growth Fwd 2Yr
3.53%

Metric	Dec '14	Jan '16	Jan '17	Dec '17	Dec '18	Dec '19	Jan '21	Jan '22	Jan '23	Dec '23	LTM
Total Revenues						82,059	82,584	78,740	79,990	85,159	85,648
Total Revenues % Chg.						0.6%	0.6%	-4.7%	1.6%	6.5%	-11%
Cost of Goods Sold, Total						27,556	28,427	23,402	24,596	26,244	26,268
Gross Profit						54,503	54,157	55,338	55,394	58,915	59,380
Selling General & Admin Expenses, Total						21,885	21,731	19,506	19,078	20,166	20,520
R&D Expenses						11,355	12,159	14,277	14,135	15,085	15,186
Other Operating Expenses, Total						33,240	33,890	33,783	33,213	35,251	35,706
Operating Income						21,263	20,267	21,555	22,181	23,664	23,674
Interest Expense, Total						-318	-201	-183	-276	-772	-758
Interest And Investment Income						357	111	53	490	1,261	1,470
Net Interest Expenses						39	-90	-130	214	489	712
Currency Exchange Gains (Loss)						-267	-209	-216	-286	-366	-366
Other Non Operating Income (Expenses)						-3,909	-2,922	-550	1,744	1,664	1,816
EBT, Excl. Unusual Items						17,126	17,046	20,659	23,853	25,451	25,836
Restructuring Charges	—					-266	-247	-209	-275	-798	-839
Merger & Related Restructuring Charges			—	—	—	—	—	—	-300	-200	-306
Gain (Loss) On Sale Of Investments	—	—	—	—	—	300	1	—	-700	-600	-508
Gain (Loss) On Sale Of Assets						2,154	111	617	380	117	117
Asset Writedown	—					-1,096	-233	-989	-1,216	-1,295	-1,295
In Process R&D Expenses						-890	-181	-900	-783	-313	-264
Legal Settlements			—	—	—	—	—	—	-900	-6,900	—
Other Unusual Items	—	—	—	—	—	—	—	—	-700	-400	48
EBT, Incl. Unusual Items						17,328	16,497	19,178	19,359	15,062	22,789
Income Tax Expense						2,209	1,783	1,377	2,989	1,736	3,618
Earnings From Continuing Operations						15,119	14,714	17,801	16,370	13,326	19,171
Earnings Of Discontinued Operations	—	—	—	—	—	—	—	3,077	1,571	21,827	21,404
Net Income						15,119	14,714	20,878	17,941	35,153	40,575
Net Income to Common Incl Extra Items						15,119	14,714	20,878	17,941	35,153	40,575
Net Income to Common Excl. Extra Items						15,119	14,714	17,801	16,370	13,326	19,171
Total Shares Outstanding						2,632.5	2,632.5	2,629	2,613.6	2,407.1	2,430.1
Weighted Avg. Shares Outstanding						2,645.1	2,632.8	2,632.1	2,625.2	2,533.5	2,489.7
Weighted Avg. Shares Outstanding Dil						2,684.3	2,670.7	2,674	2,663.9	2,560.4	2,516.6
EPS						5.7	5.6	7.9	6.8	13.9	16.3
EPS Diluted						5.6	5.5	7.8	6.7	13.7	16.1
EBITDA						28,272	27,498	28,206	28,510	30,767	30,672.8
Effective Tax Rate						12.7%	10.8%	7.2%	15.4%	11.5%	15.9%